Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Oct 2020 · 1 min read
In brief
In brief
Phase 2 international trial evaluating tazemetostat, an oral EZH2 inhibitor, in patients with advanced epithelioid sarcoma characterized by INI1/SMARCB1 loss. The study enrolled patients across nine countries to assess objective response rates and survival outcomes in this rare, aggressive soft-tissue malignancy with oncogenic dependence on EZH2.
Written by the GCMD Library team from the article.
Statements in this article
Over 90% of epithelioid sarcomas have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2.
Eligible patients were aged 16 years or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma.
Patients required documented loss of INI1 expression by immunohistochemical analysis or biallelic SMARCB1 alterations, or both.
Eligible patients had an Eastern Cooperative Oncology Group performance status score of 0-2.
Patients received 800 mg tazemetostat orally twice per day in continuous 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent.
The primary endpoint was investigator-assessed objective response rate measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1.